Strategic Partnerships Mikart’s recent co-marketing partnership with Benuvia Therapeutics and collaboration history with Nano PharmaSolutions and Fluid Pharma indicate openness to strategic alliances. This presents a sales opportunity to propose joint development, access to CSO/CMC support, or bundled services that leverage Mikart’s solid dose manufacturing and specialized API capabilities to broaden market reach.

Expansion footprint The opening of a new headquarters in Northwest Atlanta signals scale-up and regional capacity. Approach as a prospect for contract manufacturing expansions, on-site pilot lines, or increased capacity for late-stage development and commercial manufacturing to support growing client portfolios.

CDMO niche Mikart specializes in solid dose and non-sterile liquid dosage forms with development to commercialization support. This makes them a strong target for companies seeking end-to-end CDMO services, especially those with PhRMA, specialty pharma, or biotech pipelines requiring rapid scaling, formulation optimization, and packaging expertise.

Technology leverage Adoption of advanced equipment such as Fette double-sided tablet presses and collaboration with tech partners suggests capability to improve throughput and quality. Sales opportunities exist to position Mikart as a technology-forward partner for complex formulations, high-volume tablets, and enhanced analytics or digital documentation workflows.

Financial scale With estimated revenue between $250M and $500M and a growing employee base, Mikart represents a mid-market CDMO with substantial production capacity and resources. This profile is attractive for long-term outsourcing deals, risk-sharing manufacturing arrangements, and extended service agreements that require reliable, financially stable partners.